On the stock market since 2021, it operates in the world of health and science. It has 26 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
There is $60.2M in the vault; even if every debt were paid off, $60.1M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 12 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $8.9M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 2/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 49/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, DRUG sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: DRUG is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.